Regenxbio Inc (RGNX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $505.18M
Last updated: Nov 17, 2026 at 11:05 AM ET
Regenxbio Inc (RGNX) Stock Forecast
Analysts expect Regenxbio (RGNX) to earn -$3.58 per share in the fiscal year ending Dec 31, 2026, on revenue of $159.62M. Of 11 analysts, 10 rate the stock Buy or Strong Buy, 1 Hold and 0 Sell or Strong Sell, for a consensus of Buy. For the fiscal year ending Dec 31, 2027, the EPS consensus is -$3.28.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 11 ratings average 1.82, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 91% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 3 | 27.3% |
| Buy | 7 | 63.6% |
| Hold | 1 | 9.1% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 11
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates rise 24.0%.
- Fiscal year ending Dec 31, 2026
- -$3.58
- EPS consensus, revenue $159.62M
- Fiscal year ending Dec 31, 2027
- -$3.28
- EPS consensus, revenue $197.93M
- Next report
- Mar 3, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$3.58 | -$4.39 to -$3.16 | 4 | $159.62M | $130.10M to $302.70M | 7 |
| Dec 31, 2027 | -$3.28 | -$4.79 to -$0.21 | 5 | $197.93M | $28.00M to $417.10M | 8 |
Quarterly Estimates
The EPS consensus rises from -$1.01 for the quarter ending Dec 31, 2026 to -$0.99 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$1.01 | -$1.86 to $1.21 | 13 | $28.87M | $6.17M to $169.05M | 11 |
| Mar 31, 2027 | -$0.99 | -$0.99 to -$0.99 | 1 | $9.00M | $7.00M to $10.00M | 3 |
Estimate Revisions
Across the 2 periods below, the last 30 days brought 3 upward and 2 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2027 | 2 | 1 |
| Quarter ending Mar 31, 2027 | 1 | 1 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$3.43.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$3.58 | -$3.46 | -$3.49 | -$3.52 | -$3.43 | N/A |
| Fiscal year ending Dec 31, 2027 | -$3.28 | -$2.95 | -$2.98 | -$3.00 | -$2.31 | N/A |
| Quarter ending Mar 31, 2027 | -$0.99 | -$1.23 | -$1.23 | -$1.23 | -$0.32 | N/A |
Frequently Asked Questions About RGNX
What is the RGNX stock forecast?
Consensus analyst estimates put Regenxbio's EPS at -$3.58 for the fiscal year ending Dec 31, 2026, on revenue of $159.62M. The consensus rating from 11 analysts is Buy.
How do analysts rate RGNX stock?
Of 11 analysts covering Regenxbio, 3 rate it Strong Buy, 7 Buy, 1 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from RGNX next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$3.58, with estimates from -$4.39 to -$3.16 from 4 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$3.28, with estimates from -$4.79 to -$0.21 from 5 analysts.
What revenue do analysts expect from Regenxbio next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $159.62M, with estimates from $130.10M to $302.70M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $197.93M, with estimates from $28.00M to $417.10M.
How many analysts cover RGNX?
11 analysts rate Regenxbio stock, and 4 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
RGNX pages: Overview, Earnings, Forecast, Financials, Competitors